UPDATE: William Blair Initiates Coverage on Infinity Pharmaceuticals on Multiple Challenges Ahead

In a report published Tuesday, William Blair & Company analyst Y. Katherine Xu initiated coverage on Infinity Pharmaceuticals (NASDAQ: INFI ) with a Market Perform rating and $21.00 price target. In the report, William Blair & Company noted, “Infinity's IPI-145 is a follower to ibrutinib in a different class with